Uncategorized
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
DUBLIN--(BUSINESS WIRE)--New data from Phase 3 teprotumumab study shows significant benefit on several devastating effects of active thyroid eye disease (TED).